Ovid Therapeutics (OVID) Cash from Investing Activities (2016 - 2026)

Ovid Therapeutics (OVID) has reported Cash from Investing Activities for 11 consecutive years, with -$86.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 819.65% year-over-year to -$86.7 million; the trailing twelve-month figure through Jun 2026 stood at -$147.8 million (down 481.53% YoY), and the FY2025 full-year result was -$49.9 million, down 191.32% from the prior year.
• Cash from Investing Activities fell to -$86.7 million in Q2 2026 per OVID's latest filing, from $5.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $30.2 million in Q1 2023 and bottomed at -$86.7 million in Q2 2026.
• Historically, Cash from Investing Activities has averaged -$9.3 million across 5 years, with a median of $2.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 9246.58% in 2022, then surged 2908.96% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$4.2 million in 2022, then sank by 1063.59% to -$48.5 million in 2023, then soared by 143.89% to $21.3 million in 2024, then sank by 438.45% to -$72.1 million in 2025, then declined by 20.37% to -$86.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$86.7 million, $5.9 million, and -$72.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.